// App-Quantinova.ai

TPS6592 : CCTG HN.10: A phase II single-arm trial of elective volume adjusted de-escalation radiotherapy (EVADER) in patients with low-risk HPV-related oropharyngeal squamous cell carcinoma (NCT03822897).

Researchers

Presenter

  • Scott Victor Bratman

Principal Investigators

  • Eric Berthelet

  • James B. Butler

  • John R de Almeida

  • Irene Karam

  • Ur Metser

  • Robert Anton Olson

  • Craig Pochini

  • John Waldron

  • Eugene Yu

  • Andrea McNiven

  • Winson Y. Cheung

  • Marc Gaudet

  • Sarah Hunter

  • Bingshu E. Chen

  • Wendy R. Parulekar

Medical Centers

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • BC Cancer Agency, Vancouver, BC, Canada

  • Cancer Care Manitoba, Winnipeg, MB, Canada

  • Department of Otolaryngology-Head & Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Joint Department of Medical Imaging, University of Toronto Health Network, Toronto, ON, Canada

  • BC Cancer Agency, Vancouver, BC, Canada

  • Eastern Health, St. John, NB, Canada

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Radiation Medicine Program Princess Margaret Cancer Centre, Toronto, ON, Canada

  • The Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • Canadian Cancer Trials Group, Kingston, ON, Canada

  • Canadian Cancer Trials Group, Kingston, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • NA

Study Id's

  • NCT03822897

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved